Treatment with GLP-1RAs improves exocrine pancreatic function in patients with T2D

Key clinical point: Treatment with both long-acting (liraglutide) and short-acting (lixisenatide) glucagon-like peptide-1 receptor agonists (GLP-1RAs) significantly improved exocrine pancreatic function in patients with type 2 diabetes (T2D).

Major finding: Fecal elastase levels increased with lixisenatide (+46.6±17.7 mg/g; P = .015) and liraglutide (+30.3±14.3 mg/g; P = .045) treatment. b-carotene levels increased with lixisenatide (+0.05±0.02 mmol/L; P = .022) but not with liraglutide (−0.00±0.02 mmol/L; P = .96) treatment. Levels of lipase and amylase increased with liraglutide (P = .0001 and P = .013, respectively) but not with lixisenatide (P = .46 and P = .93, respectively).

Study details: This study included 50 patients with T2D randomly assigned to receive a 10-week treatment of either lixisenatide (n=24) or liraglutide (n=26).

Disclosures: This study was sponsored by Novo Nordisk. Some investigators reported ties with various pharmaceutical companies including Novo Nordisk.

Source: Quast DR et al. Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14477.

Key clinical point: Treatment with both long-acting (liraglutide) and short-acting (lixisenatide) glucagon-like peptide-1 receptor agonists (GLP-1RAs) significantly improved exocrine pancreatic function in patients with type 2 diabetes (T2D).

Major finding: Fecal elastase levels increased with lixisenatide (+46.6±17.7 mg/g; P = .015) and liraglutide (+30.3±14.3 mg/g; P = .045) treatment. b-carotene levels increased with lixisenatide (+0.05±0.02 mmol/L; P = .022) but not with liraglutide (−0.00±0.02 mmol/L; P = .96) treatment. Levels of lipase and amylase increased with liraglutide (P = .0001 and P = .013, respectively) but not with lixisenatide (P = .46 and P = .93, respectively).

Study details: This study included 50 patients with T2D randomly assigned to receive a 10-week treatment of either lixisenatide (n=24) or liraglutide (n=26).

Disclosures: This study was sponsored by Novo Nordisk. Some investigators reported ties with various pharmaceutical companies including Novo Nordisk.

Source: Quast DR et al. Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14477.

Key clinical point: Treatment with both long-acting (liraglutide) and short-acting (lixisenatide) glucagon-like peptide-1 receptor agonists (GLP-1RAs) significantly improved exocrine pancreatic function in patients with type 2 diabetes (T2D).

Major finding: Fecal elastase levels increased with lixisenatide (+46.6±17.7 mg/g; P = .015) and liraglutide (+30.3±14.3 mg/g; P = .045) treatment. b-carotene levels increased with lixisenatide (+0.05±0.02 mmol/L; P = .022) but not with liraglutide (−0.00±0.02 mmol/L; P = .96) treatment. Levels of lipase and amylase increased with liraglutide (P = .0001 and P = .013, respectively) but not with lixisenatide (P = .46 and P = .93, respectively).

Study details: This study included 50 patients with T2D randomly assigned to receive a 10-week treatment of either lixisenatide (n=24) or liraglutide (n=26).

Disclosures: This study was sponsored by Novo Nordisk. Some investigators reported ties with various pharmaceutical companies including Novo Nordisk.

Source: Quast DR et al. Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14477.